Find Clinical Trial

Home » Find Clinical Trials » A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)

A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)

← Back

Study Phase	Phase 3

Therapeutic Area	Rheumatology

Indication	Osteoporosis

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	STRONTIUM RANELATE, S012911

Active Substance Code	S012911

Protocol Code	CL3-12911-019

ISRCTN Code	ISRCTN82719233

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.